肿瘤睾丸抗原在肝细胞癌中的研究进展  

Research progress of tumor testis antigen in hepatocellular carcinoma

作　　者：呼胜楠(综述) 完迪迪 杨小昂(审校) HU Shengnan;WAN Didi;YANG Xiao′ang(Henan Provincial Institute of Medical and Pharmaceutical Sciences,Zhengzhou University,Zhengzhou,Henan 450052,China;Huanghe Science and Technology University,Zhengzhou,Henan 450063,China;Henan Provincial Key Laboratory for Pharmacology of Liver Diseases,Zhengzhou,Henan 450052,China)

机构地区：[1]郑州大学河南省医药科学研究院肝病研究所,郑州450052 [2]黄河科技学院,郑州450063 [3]河南省肝病药理重点实验室,郑州450052

出　　处：《重庆医学》2021年第9期1605-1608,共4页Chongqing medicine

基　　金：河南省自然科学基金项目(182300410343);河南省科技攻关项目(182102310280)。

摘　　要：肿瘤睾丸抗原(CTA)是一组肿瘤相关抗原,在不同癌症中均有表达,而在睾丸除外的正常组织中不表达。由于CTA呈现限制性表达模式,并具有引起患者产生免疫应答的能力,使CTA成为肿瘤免疫治疗中有应用前景的一类抗原。有研究表明在肝细胞癌(HCC)患者组织和外周血样品中存在CTA的表达,而癌旁组织和正常肝组织中均未表达,为CTA成为HCC患者免疫治疗的潜在靶向标志物奠定了基础。本综述旨在探讨CTA有望作为HCC生物标志物和免疫治疗靶点的临床意义。Cancer testis antigen(CTA)is a group of tumor-associated antigens,which is expressed in different cancers,but is not expressed in normal tissues other than testis.Because CTA presents a restricted expression pattern and has the ability causing the immune response in cancer patients,CTA has become a class of antigens with potential application in tumor immunotherapy.Some studies indicate that the CTA expression exists in the tissues and peripheral blood samples of hepatocellular carcinoma(HCC)patients,but CTA has no expression in paracancerous tissues and normal liver tissues,which lays the foundation for CTA becoming a potential target marker for immunotherapy in HCC patients.This review aims to explore the clinical significance of CTA expecting to be a biomarker and immunotherapeutic target point of HCC.

关 键 词：肿瘤睾丸抗原 癌 肝细胞 肿瘤转移 预后 

分 类 号：R735.7[医药卫生—肿瘤]